Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Slides:

Advertisements

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Advertisements

Soft robotic device applied to the RV in a pressure overload model of RHF. Soft robotic device applied to the RV in a pressure overload model of RHF. (A.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

Specific depletion of TFH and LCMV-specific CD4 T cells.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Specific depletion of CD4-DTR–derived CD4 T cells.

Three different types of transfer functions with a codomain of [0,1].

Ex vivo testing of the soft robotic devices.

Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.

A novice user executing various subtasks from study 1.

Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.

Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria. Inhibiting or altering.

Online verification using reachable occupancies.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

CXCR5+/+ TFH cells are essential for the generation of LCMV-neutralizing antibodies and clearance of a persistent LCMV infection. CXCR5+/+ TFH cells are.

Fig. 3 The electrical contact of direct-printed and reconfigured liquid metals. The electrical contact of direct-printed and reconfigured liquid metals.

Experimental results for healthy participants.

LIMK1 inhibition protects against Aβ-induced neuronal hyperexcitability. LIMK1 inhibition protects against Aβ-induced neuronal hyperexcitability. (A) Representative.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Microrobots with different cell-carrying capacities under different grid lengths (lg) and burr lengths (lb). Microrobots with different cell-carrying capacities.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Vaccine MN confer protective innate and adaptive immunity.

Inhibition of CDK9 by UNC drives MYC loss.

Fig. 2 CD19 CAR T cells expressing tPSMA maintain function in vitro and in vivo. CD19 CAR T cells expressing tPSMA maintain function in vitro and in vivo.

Soft robotic device applied to the RV in a pressure overload model of RHF. Soft robotic device applied to the RV in a pressure overload model of RHF. (A.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

CD25 surface expression and TCR signal strength predict T helper differentiation and memory potential of early effector T cells in vivo. CD25 surface expression.

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Tfr cells respond better to immunization with self-antigens than with foreign antigens. Tfr cells respond better to immunization with self-antigens than.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Fig. 1 Impacts of intensified acidification on stream pH and calcium concentration. Impacts of intensified acidification on stream pH and calcium concentration.

Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria and worsened colitis upon.

Sensitivity analysis of cellular responses to perturbation of the DNA damage response signaling in the presence of chemotherapies. Sensitivity analysis.

AEGIS autonomous targeting process.

Fig. 4 Neonatal rGM-CSF corrects increased SP-D in LPL−/− mice.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Fig. 3 Production of protein and Fe(II) at the end of growth correlated with increasing concentrations of ferrihydrite in the media that contained 0.2.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. CDs with KRASG12C cooperatively sustain downstream.

Combination therapies targeting CDs with KRASG12C differ in their ability to promote S-IIP target engagement. Combination therapies targeting CDs with.

Fig. 1 WNT antagonists synergize with taxanes.

Fig. 1 Location of the Jirzankal Cemetery.

UNC drives MYC protein loss.

Discrimination accuracy across conditions.

Fig. 6 The combined therapeutic efficacy of N-pepABS and low dose of Dox on MDA-MB-231 xenografts. The combined therapeutic efficacy of N-pepABS and low.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

PDL192 and inhibit the growth of xenograft tumors.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 6 Stabilization of hippocampal signaling over sleep.

AV3 potentiates the effect of gemcitabine in the PDX model in mice

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 4 In vivo siRIPK4 delivered by HNTs inhibits tumor promotion of T24 bladder cancer cells in an in situ model of bladder cancer (n = 12 rats in each.

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

Fetal-derived γδ T cells infiltrate the meninges from birth.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Fig. 5 CD19-tPSMA(N9del) CAR T cell numbers in mouse and human.

Presentation transcript:

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. (A) Tumor volumes in mice bearing H358 xenografts and treated with vehicle, ARS-1620 (100 mg/kg), erlotinib (80 to 100 mg/kg, EGFRi), or their combination. Treatment was stopped 54 days after initial implantation to monitor the durability of observed responses. n ≥ 4 mice per group; error bars denote SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 comparing ARS-1620 and combination arms by a Mann-Whitney test. (B) Tumor volumes in mice bearing MIA PaCa-2 xenografts and treated with vehicle, ARS-1620 (100 mg/kg), palbociclib (100 mg/kg, CDK4/6i), or their combination. n ≥ 8 mice per group; error bars denote SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 comparing ARS-1620 and combination arms by a Mann-Whitney test. Kevin Lou et al., Sci. Signal. 2019;12:eaaw9450 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works